Semax — Wolverine Health

How it works

A synthetic heptapeptide based on the 4–10 fragment of ACTH, engineered to retain neurotrophic properties without hormonal activity. In animal models it increases BDNF and NGF, supports neurogenesis, and shows neuroprotective effects after ischemia. A registered medicine in Russia for stroke recovery and cognitive decline. The non-Russian clinical trial base is small — the neurotrophic mechanism is real, the human benefit in healthy people is not established.

FDA status: No FDA approval. Under PCAC July 23–24 2026 review. Registered drug in Russia for stroke and cognitive impairment indications.
WADA status: Permitted in sport
Route: intranasal

Key studies

Nootropic peptides from the ACTH family — Kost et al.

Semax, a synthetic heptapeptide derived from the ACTH 4-10 fragment, retains neurotrophic properties without adrenocorticotropic activity and increases BDNF expression in rodent brain tissue.

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on Semax

Semax: A Real Peptide With a Clinical Record the West Can't Audit

Semax has a documented mechanism and a quarter-century of authorised use in Russia. Whether either of those things adds up to evidence a Western reader can actually check is a separate, unresolved question.

PCAC: The FDA Committee Deciding Whether BPC-157 Stays Legal to Compound

PCAC decided something about BPC-157 in July 2026, and most of the peptide world still can't say what, or what it doesn't mean.

What RFK Jr.'s February 2026 announcement actually said about peptides

The "announcement" was a Joe Rogan appearance, not a Federal Register notice. The wellness scene heard one thing. The actual signal was narrower, and the rulemaking that turns it into access is still more than a year away.

The PCAC review happened July 23–24, 2026. Here is what that means for peptide access.

Two days at FDA's White Oak campus decided which of seven peptides US compounding pharmacies may eventually dispense by prescription. The recommendation is not an approval, the docket is not all the peptides, and the framing the forums used going in was mostly wrong.

Peptide bioavailability: why your peptide is a needle, not a pill

WADA

Most peptides come as a vial and a needle for one reason — swallow them and your gut destroys them before they can work. Understanding how a peptide actually gets into your body is the single lens that tells you whether a product can work at all. Here is how it works, in plain English.

Your stress switch: how the HPA axis works, and where Selank and Semax reach into it

WADA

Your body has a switch for stress — it should flip on under load and off when it passes. When it stops flipping off, you get the wired-and-foggy version most men know. Here is how that switch works, and how two Russian peptides could help it behave.

Selank vs Semax: the calm one and the sharp one

WADA

Selank and Semax get sold side by side as brain peptides, but they solve opposite problems — one calms, one sharpens. Here's what each could do for you, how far the Russian evidence actually goes, and why the July 2026 FDA review splits them apart.

Semax: the brain-protection peptide Russia has used for thirty years

WADA

Semax is a Russian brain peptide with an unusual credential — three decades of real clinical use in stroke care, not just a biohacker rumour. Here is what it could do across neuroprotection and focus, how far the proof runs, and its spot on the FDA's July 2026 PCAC docket.